Bisphosphonate-Quinolone Conjugates for Targeted Bone Infection Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for bone infections such as osteomyelitis are long and difficult, often requiring surgical intervention, highlighting a need for improved therapeutic options.
Innovation Solution
Development of bisphosphonate (BP) quinolone conjugates that selectively deliver quinolones to bone tissues, allowing for targeted treatment of bone infections and diseases through releasable conjugation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibiotic treatments are used for osteomyelitis, then the infection can be treated, but the treatment is lengthy and requires surgical intervention
Solution Approach 1:
The conjugate molecule is segmented into distinct functional components: a bisphosphonate segment for bone targeting, a linker segment for stable conjugation, and a quinolone segment for antimicrobial activity. This segmentation allows each component to perform its specific function independently, enabling targeted delivery that reduces treatment duration while maintaining efficacy.
Solution Approach 2:
The bisphosphonate acts as an intermediary carrier that facilitates the delivery of the quinolone antibiotic to bone tissue. The bisphosphonate-quinolone conjugate serves as an intermediary molecule that combines the bone-targeting properties of bisphosphonates with the antimicrobial properties of quinolones, thereby reducing the need for prolonged treatment and surgical intervention.
2Reliability
If conventional antibiotic treatments are used for bone infections, then the infection can be addressed, but poor antibiotic penetration in bone tissue occurs
Solution Approach 1:
The conjugate exhibits local quality by concentrating the quinolone antibiotic specifically at bone tissue through the bisphosphonate's bone affinity. This local concentration mechanism ensures high antibiotic levels at the infection site while minimizing systemic exposure, thereby overcoming the problem of poor penetration without requiring increased doses.
Solution Approach 2:
The bisphosphonate serves as an intermediary delivery vehicle that penetrates bone tissue and releases the quinolone antibiotic at the target site. This intermediary mechanism overcomes the penetration barrier by utilizing the bisphosphonate's ability to bind to bone mineral, thereby delivering the antibiotic directly to the infection site.
3Reliability
If conventional antibiotic treatments are used for bone infections, then the infection can be treated, but biofilm-mediated antimicrobial resistance develops
Solution Approach 1:
The conjugate performs preliminary action by delivering the quinolone antibiotic directly to the bone infection site before the bacteria can develop resistance mechanisms. The targeted delivery ensures high local concentrations that can penetrate biofilms and eliminate pathogens before resistance can establish, thereby preventing biofilm-mediated resistance.
Solution Approach 2:
The conjugate changes the pharmacokinetic parameters of the quinolone antibiotic by altering its delivery mechanism from systemic circulation to targeted bone delivery. This parameter change results in higher local concentrations and improved penetration into biofilms, thereby overcoming antimicrobial resistance while maintaining effective treatment.
4Reliability
If systemic antibiotic administration is used, then the infection can be treated, but systemic toxicity increases
Solution Approach 1:
The conjugate provides local quality by concentrating the antibiotic action specifically at bone tissue through the bisphosphonate's selective binding. This local concentration mechanism achieves effective treatment while minimizing systemic exposure and associated toxicity, as the quinolone is released primarily at the bone infection site rather than circulating systemically.
Solution Approach 2:
The bisphosphonate-quinolone conjugate acts as an intermediary that prevents direct systemic circulation of the quinolone antibiotic. The conjugate structure ensures that the quinolone is released locally at bone sites, thereby treating the infection while avoiding the systemic toxicity that would result from conventional systemic administration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The BP quinolone conjugates effectively kill or inhibit bacterial growth, treat bone diseases, and prevent infections by selectively targeting bone tissues, offering a non-surgical alternative with enhanced efficacy.
Implementation Method 1
the BP quinolone conjugate can selectively deliver a quinolone to bone, bone grafts, and or bone graft substitutes
Implementation Method 2
a bisphosphonate (BP) that can be releasably conjugated to a quinolone
Data Source
AI summary
Described herein are bisphosphonate quinolone compounds, conjugates and pharmaceutical formulations thereof that can include a bisphosphonate and a quinolone, where the quinolone can be releasably coupled to the bisphosphonate. Also provided herein are methods of making and methods of using the bisphosphonate quinolone compounds, conjugates and pharmaceutical formulations thereof.